A molecular bioscientist, Kathryn has had a distinguished career in diverse leadership and strategic roles across the public and private sectors.
Following a successful research career at the University of Manchester, Harvard Medical School, Wellcome Trust Sanger Institute and GlaxoSmithKline, Kathryn has played a pivotal role in shaping inclusive innovation landscapes, building cross-disciplinary virtual and physical communities and creating novel models to remove barriers to success.
This includes a decade building and leading the innovation strategy for NC3Rs, a UKRI Research Council where Kathryn founded and directed a new challenge-led open innovation platform, CRACK IT which increases cross-discipline and cross-sector industry/academic partnerships in applied research. Kathryn also co-established the Milner Therapeutics Institute at the University of Cambridge, providing a physical hub for translational science and collaboration between industry and academia. The Institute is a centre of excellence for target validation through artificial intelligence, machine-learning, functional genomics and tool compound analyses. Most recently, prior to joining Innovate Cambridge, Kathryn directed the innovation strategy at the Babraham Research Campus, launching LiveLabs incubator space and leading the Campus accelerator, entrepreneurship and innovation activities.
Throughout these roles. Chapman’s focus has been on spearheading initiatives that propel startups, entrepreneurs and businesses towards success and driving meaningful change at a national and international level.
Kathryn has 50+ research publications and has been on a wide-range of national and international review panels (Innovate UK, Innovative Medicines Initiative and BBSRC). She holds an honorary professorship at the University of Coventry where she sits on the Vice Chancellor’s advisory group.